Ipilimumab

Search with Google Search with Bing

Information
Drug Name
Ipilimumab
Description
Entry(CIViC)
2
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
Sezary's disease CTLA4 CTLA4-CD28 C Predictive Supports Sensitivity/Response Somatic 2 25802883 Detail
melanoma CD274 EXPRESSION CD274 EXPRESSION B Predictive Does Not Support Sensitivity/Response Somatic 3 23724867 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
A 67-year-old Caucasian female with stage IVA Seza... CTLA4 CTLA4 CTLA4-CD28 Sensitivity true CIViC Evidence detail
A clinical trial of 86 patients evaluated concurre... CD274 CD274 EXPRESSION CD274 EXPRESSION Sensitivity false CIViC Evidence detail
Phase II randomized dose ranging study (metastatic... CTLA4 CTLA4 UNKNOWN Sensitivity true MMMP detail
In a multicenter single-arm phase II trial of ipil... CTLA4 CTLA4 UNKNOWN Resitance or Non-Reponse true MMMP detail
Phase III RCT. Setting: metastatic, all patients w... CTLA4 CTLA4 UNKNOWN Sensitivity true MMMP detail
Influence of cytotoxic T lymphocyte-associated ant... CTLA4 CTLA4 rs4553808 rs4553808
( ENST00000696479.1 ) 		Sensitivity true MMMP detail
Influence of cytotoxic T lymphocyte-associated ant... CTLA4 ALOX12 rs11571327 Sensitivity true MMMP detail
Influence of cytotoxic T lymphocyte-associated ant... CTLA4 CTLA4 p.Thr17Ala (p.T17A)
( ENST00000295854.10, ENST00000487393.1, ENST00000648405.2, ENST00000696049.1, ENST00000696479.1 ) CTLA4 p.Thr17Ser (p.T17S)
( ENST00000295854.10, ENST00000487393.1, ENST00000648405.2, ENST00000696049.1, ENST00000696479.1 ) 		Sensitivity true MMMP detail
Influence of cytotoxic T lymphocyte-associated ant... CTLA4 rs733618
( ENST00000696479.1 ) 		Resitance or Non-Reponse true MMMP detail
Influence of cytotoxic T lymphocyte-associated ant... CTLA4 NC_000002.12:g.203867624C>T
( ENST00000696479.1 ) 		Resitance or Non-Reponse true MMMP detail
Influence of cytotoxic T lymphocyte-associated ant... CTLA4 CTLA4 rs3087243 CTLA4 c.*1148+236G>A Resitance or Non-Reponse true MMMP detail
Influence of cytotoxic T lymphocyte-associated ant... CTLA4 rs7565213 rs7565213 Resitance or Non-Reponse true MMMP detail
In this phase I-II trial, a 39% disease control ra... CTLA4 CTLA4 UNKNOWN Sensitivity true MMMP detail
A phase II RCT showed that budesonide (an oral non... NR3C1 NR3C1 OVEREXPRESSION toxicity unchanged true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT01658878 Active, not recruiting Phase 1/Phase 2 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer October 30, 2012 June 28, 2024
NCT02428192 Active, not recruiting Phase 2 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma April 22, 2015 March 5, 2025
NCT04039607 Active, not recruiting Phase 3 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma September 30, 2019 September 30, 2026
NCT02453620 Active, not recruiting Phase 1 Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer February 12, 2016 August 30, 2024
NCT04463368 Active, not recruiting Phase 1 Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases March 8, 2021 December 1, 2024
NCT02477826 Active, not recruiting Phase 3 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) August 5, 2015 August 30, 2024
NCT04396860 Active, not recruiting Phase 2/Phase 3 Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma September 1, 2020 March 11, 2025
NCT02496208 Active, not recruiting Phase 1 Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors July 22, 2015 September 30, 2024
NCT02498600 Active, not recruiting Phase 2 Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer June 29, 2015 December 31, 2024
NCT04026412 Active, not recruiting Phase 3 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery October 8, 2019 December 3, 2026
NCT05704933 Active, not recruiting Early Phase 1 Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases June 6, 2023 January 2027
NCT04021043 Active, not recruiting Phase 1/Phase 2 BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers August 19, 2019 August 29, 2024
NCT02506153 Active, not recruiting Phase 3 Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery November 10, 2015 January 23, 2025
NCT01676649 Active, not recruiting Phase 2 Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma November 2012 May 2026
NCT01928394 Active, not recruiting Phase 1/Phase 2 A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors October 24, 2013 October 31, 2024
NCT02530463 Active, not recruiting Phase 2 Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome September 8, 2015 September 30, 2025
NCT01274338 Active, not recruiting Phase 3 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery May 25, 2011 March 7, 2025
NCT04362839 Active, not recruiting Phase 1 Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer May 27, 2020 June 30, 2024
NCT04361162 Active, not recruiting Phase 2 Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer May 18, 2020 October 2026
NCT01950390 Active, not recruiting Phase 2 Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery January 24, 2014 January 7, 2025
NCT04013542 Active, not recruiting Phase 1 Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer September 13, 2019 December 31, 2024
NCT04317105 Active, not recruiting Phase 1/Phase 2 Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN July 17, 2020 December 31, 2024
NCT01688492 Active, not recruiting Phase 1/Phase 2 Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer September 2012 September 2024
NCT04868760 Active, not recruiting Phase 1 A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers June 4, 2021 December 6, 2022
NCT04300244 Active, not recruiting Phase 2 Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma May 4, 2020 March 15, 2027
NCT04863885 Active, not recruiting Phase 1/Phase 2 Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients April 30, 2021 October 2025
NCT02017717 Active, not recruiting Phase 3 A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients February 7, 2014 April 8, 2024
NCT02020070 Active, not recruiting Phase 2 Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy December 18, 2013 December 2025
NCT02668770 Active, not recruiting Phase 1 Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies May 11, 2016 May 31, 2025
NCT03999749 Active, not recruiting Phase 2 A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma June 11, 2019 November 1, 2024
NCT03937219 Active, not recruiting Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma June 25, 2019 March 2025
NCT02696993 Active, not recruiting Phase 1/Phase 2 Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer December 16, 2016 December 31, 2024
NCT02703623 Active, not recruiting Phase 2 Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer May 18, 2016 March 31, 2026
NCT03929029 Active, not recruiting Phase 1 Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma November 11, 2020 September 30, 2028
NCT05220722 Active, not recruiting Phase 1/Phase 2 Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors March 2, 2022 January 2025
NCT04781855 Active, not recruiting Phase 1 Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation July 14, 2022 December 31, 2024
NCT01701674 Active, not recruiting N/A Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts October 9, 2012 December 15, 2025
NCT04270864 Active, not recruiting Phase 1 Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers April 10, 2020 February 2026
NCT02743819 Active, not recruiting Phase 2 Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma June 28, 2016 June 2026
NCT03914300 Active, not recruiting Phase 2 Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer February 10, 2020 October 31, 2024
NCT02785952 Active, not recruiting Phase 3 Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers December 29, 2015 April 1, 2025
NCT05169957 Active, not recruiting Phase 1 Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) August 9, 2022 June 13, 2025
NCT04247165 Active, not recruiting Phase 1/Phase 2 Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. June 2, 2020 December 2024
NCT02060188 Active, not recruiting Phase 2 A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread March 12, 2014 June 28, 2024
NCT02834013 Active, not recruiting Phase 2 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors January 30, 2017 May 1, 2026
NCT03912064 Active, not recruiting Phase 1 A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT July 10, 2019 July 1, 2024
NCT02068196 Active, not recruiting Phase 4 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. January 2014 December 2026
NCT01708941 Active, not recruiting Phase 2 Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery January 18, 2013 March 7, 2025
NCT02872116 Active, not recruiting Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer October 12, 2016 May 31, 2024
NCT02879695 Active, not recruiting Phase 1 Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia October 25, 2017 September 6, 2024
NCT04717154 Active, not recruiting Phase 2 Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer January 19, 2021 February 15, 2026
NCT02890329 Active, not recruiting Phase 1 Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia September 5, 2017 July 1, 2024
NCT03907852 Active, not recruiting Phase 1/Phase 2 Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer April 15, 2019 November 2, 2028
NCT05302921 Active, not recruiting Phase 2 Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors February 18, 2022 July 1, 2025
NCT04239040 Active, not recruiting Phase 1 GVAX Plus Checkpoint Blockade in Neuroblastoma January 29, 2020 January 1, 2027
NCT05150236 Active, not recruiting Phase 2 EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC April 29, 2022 December 2024
NCT05144854 Active, not recruiting Phase 3 A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) November 5, 2021 May 2027
NCT03873818 Active, not recruiting Phase 2 Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain February 21, 2019 August 31, 2024
NCT02919683 Active, not recruiting Phase 2 Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity November 2016 December 2024
NCT03873402 Active, not recruiting Phase 3 A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer June 21, 2019 March 11, 2025
NCT02923934 Active, not recruiting Phase 2 A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers August 22, 2017 December 2023
NCT04606316 Active, not recruiting Phase 1 Surgical Nivolumab And Ipilimumab For Recurrent GBM February 1, 2021 December 31, 2024
NCT05141721 Active, not recruiting Phase 2/Phase 3 A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer February 12, 2022 March 2027
NCT05014776 Active, not recruiting Phase 2 Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer August 22, 2022 April 3, 2025
NCT04967196 Active, not recruiting Phase 1 Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma September 16, 2021 July 2025
NCT03865082 Active, not recruiting Phase 2 Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) October 29, 2019 April 2022
NCT02950766 Active, not recruiting Phase 1 NeoVax Plus Ipilimumab in Renal Cell Carcinoma March 3, 2019 September 30, 2026
NCT04940299 Active, not recruiting Phase 2 Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma September 23, 2021 December 31, 2024
NCT04938232 Active, not recruiting Phase 2 Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL June 4, 2021 August 1, 2026
NCT02977052 Active, not recruiting Phase 2 Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab November 24, 2016 June 2025
NCT04196452 Active, not recruiting A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) June 18, 2019 June 30, 2029
NCT03829111 Active, not recruiting Phase 1 CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer May 14, 2019 June 11, 2024
NCT03818685 Active, not recruiting Phase 2 Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease July 2, 2019 May 1, 2024
NCT04141644 Active, not recruiting Phase 1 Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC August 20, 2020 April 30, 2028
NCT02985957 Active, not recruiting Phase 2 A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) March 26, 2017 January 7, 2025
NCT04133948 Active, not recruiting Phase 1/Phase 2 Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma January 7, 2020 November 2024
NCT02998528 Active, not recruiting Phase 3 A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) March 4, 2017 November 8, 2028
NCT02210117 Active, not recruiting Early Phase 1 Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery November 25, 2014 November 30, 2025
NCT01134614 Active, not recruiting Phase 2 Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery December 28, 2010 March 8, 2025
NCT03816358 Active, not recruiting Phase 1 Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer December 9, 2019 January 31, 2025
NCT04591431 Active, not recruiting Phase 2 The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy October 7, 2020 June 2025
NCT03816332 Active, not recruiting Phase 1 Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers November 8, 2019 September 22, 2024
NCT03793166 Active, not recruiting Phase 3 Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study June 7, 2019 September 15, 2024
NCT03033576 Active, not recruiting Phase 2 Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma October 23, 2017 December 12, 2024
NCT03036098 Active, not recruiting Phase 3 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer March 24, 2017 June 1, 2028
NCT02224781 Active, not recruiting Phase 3 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma September 8, 2015 December 31, 2024
NCT03789110 Active, not recruiting Phase 2 NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer March 8, 2019 June 19, 2024
NCT02231749 Active, not recruiting Phase 3 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) October 16, 2014 August 7, 2027
NCT03068624 Active, not recruiting Phase 1 Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma September 8, 2017 July 31, 2025
NCT03070392 Active, not recruiting Phase 2 Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma October 16, 2017 June 2025
NCT03071406 Active, not recruiting Phase 2 Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma March 14, 2017 July 2024
NCT03776487 Active, not recruiting Phase 2 Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer January 7, 2019 December 30, 2026
NCT03769155 Active, not recruiting Phase 1 VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma December 13, 2018 December 15, 2032
NCT03719131 Active, not recruiting Phase 2 Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy June 5, 2019 September 13, 2024
NCT05200143 Active, not recruiting Phase 2 Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma June 8, 2022 June 2031
NCT03650894 Active, not recruiting Phase 2 Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients April 3, 2019 April 2025
NCT03647969 Active, not recruiting Phase 2 Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer November 7, 2018 March 2024
NCT03122522 Active, not recruiting Phase 2 A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy April 17, 2017 April 2025
NCT04935229 Active, not recruiting Phase 1 Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma August 2, 2021 January 2025
NCT02259621 Active, not recruiting Phase 2 Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC September 2014 October 2027
NCT03600155 Active, not recruiting Phase 1 Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome October 11, 2018 March 31, 2026
NCT02275416 Active, not recruiting Phase 1/Phase 2 Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma February 2, 2015 February 2025
NCT03591731 Active, not recruiting Phase 2 Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) January 2, 2019 September 2024
NCT04575922 Active, not recruiting Phase 2 Nivolumab+Ipilimumab+RT in MSS mCRC October 5, 2020 June 2024
NCT03141177 Active, not recruiting Phase 3 A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma August 22, 2017 April 17, 2024
NCT03143153 Active, not recruiting Phase 3 A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin June 29, 2017 January 13, 2025
NCT03146650 Active, not recruiting Phase 2 Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer May 19, 2017 August 11, 2025
NCT03575793 Active, not recruiting Phase 1/Phase 2 A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer September 6, 2018 July 1, 2024
NCT01592370 Active, not recruiting Phase 1/Phase 2 An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma August 2, 2012 December 22, 2023
NCT03158129 Active, not recruiting Phase 2 Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer June 9, 2017 December 31, 2024
NCT03570619 Active, not recruiting Phase 2 Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations December 14, 2018 December 2024
NCT04887870 Active, not recruiting Phase 2/Phase 3 Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study June 30, 2021 April 19, 2025
NCT05407675 Active, not recruiting Phase 1/Phase 2 A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors August 2, 2022 October 14, 2025
NCT03552380 Active, not recruiting Phase 2 Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma August 31, 2018 August 2023
NCT03528408 Active, not recruiting Phase 2 Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma July 26, 2018 June 2023
NCT03172624 Active, not recruiting Phase 2 Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer May 26, 2017 May 2025
NCT03508570 Active, not recruiting Phase 1 Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis September 21, 2018 April 30, 2025
NCT00586391 Active, not recruiting Phase 1 CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL February 2009 July 2029
NCT02314169 Active, not recruiting Phase 2 Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer May 13, 2015 February 15, 2025
NCT03502733 Active, not recruiting Phase 1 Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma August 14, 2018 July 1, 2024
NCT03203473 Active, not recruiting Phase 2 Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) October 26, 2017 November 30, 2024
NCT04551430 Active, not recruiting Phase 2 Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma January 5, 2021 June 1, 2030
NCT03215706 Active, not recruiting Phase 3 A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC August 24, 2017 January 19, 2026
NCT03472586 Active, not recruiting Phase 2 Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver May 2, 2018 December 31, 2024
NCT03469960 Active, not recruiting Phase 3 Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr May 2, 2018 December 2024
NCT04079712 Active, not recruiting Phase 2 Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors August 6, 2020 October 1, 2024
NCT03223155 Active, not recruiting Phase 1 Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer September 7, 2017 December 2027
NCT03463408 Active, not recruiting Early Phase 1 Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma July 17, 2018 August 1, 2025
NCT02374242 Active, not recruiting Phase 2 Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases November 4, 2014 December 2028
NCT03241186 Active, not recruiting Phase 2 Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma September 12, 2017 September 2023
NCT03245892 Active, not recruiting Phase 1 A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer August 4, 2017 August 2025
NCT03246958 Active, not recruiting Phase 2 Nivolumab Plus Ipilimumab in Thyroid Cancer October 3, 2017 March 31, 2025
NCT03459222 Active, not recruiting Phase 1/Phase 2 An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread May 30, 2018 November 10, 2026
NCT04043195 Active, not recruiting Phase 1/Phase 2 Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC August 14, 2019 December 2025
NCT02388906 Active, not recruiting Phase 3 Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma March 19, 2015 October 6, 2024
NCT03274258 Active, not recruiting Phase 2 Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma December 13, 2017 July 31, 2025
NCT03449108 Active, not recruiting Phase 2 LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas April 27, 2018 June 30, 2025
NCT03285321 Active, not recruiting Phase 2 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) September 15, 2017 December 2024
NCT01844505 Active, not recruiting Phase 3 Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) June 11, 2013 October 31, 2024
NCT03442569 Active, not recruiting Phase 2 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC March 9, 2018 December 22, 2024
NCT03297593 Active, not recruiting Phase 2 Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma December 13, 2017 September 2026
NCT04480502 Active, not recruiting Phase 2 ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma December 9, 2020 October 2024
NCT04969887 Active, not recruiting Phase 2 Combination Immunotherapy in Rare Cancers Under InvesTigation August 3, 2021 March 2028
NCT03307616 Active, not recruiting Phase 2 Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery October 4, 2017 October 31, 2025
NCT03400332 Active, not recruiting Phase 1/Phase 2 A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers February 12, 2018 November 30, 2025
NCT03333616 Active, not recruiting Phase 2 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors December 28, 2017 May 31, 2025
NCT04042753 Active, not recruiting Phase 2 Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors July 31, 2019 July 2024
NCT03377361 Active, not recruiting Phase 1/Phase 2 An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread February 1, 2018 March 11, 2024
NCT03377023 Active, not recruiting Phase 1/Phase 2 Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer February 2, 2018 November 2025
NCT03369223 Active, not recruiting Phase 1/Phase 2 A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors December 6, 2017 September 19, 2024
NCT03355976 Active, not recruiting Phase 2 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas April 30, 2018 December 2025
NCT02419495 Active, not recruiting Phase 1 Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies June 26, 2015 December 31, 2024
NCT03043599 Completed Phase 1/Phase 2 Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer February 13, 2017 November 14, 2023
NCT03068455 Completed Phase 3 An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma April 11, 2017 February 2, 2021
NCT03101566 Completed Phase 2 Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer September 8, 2017 June 7, 2021
NCT03126110 Completed Phase 1/Phase 2 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies April 25, 2017 November 9, 2021
NCT03126331 Completed Phase 2 Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab August 3, 2017 October 24, 2023
NCT03130959 Completed Phase 2 A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies June 12, 2017 January 17, 2022
NCT03138512 Completed Phase 3 A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney July 7, 2017 February 1, 2024
NCT03153085 Completed Phase 2 A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma May 25, 2017 December 14, 2018
NCT03162731 Completed Early Phase 1 Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer May 11, 2017 November 16, 2022
NCT03165409 Completed Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread February 27, 2017 September 30, 2017
NCT03190265 Completed Phase 2 Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer December 14, 2017 August 23, 2023
NCT03195478 Completed Phase 1/Phase 2 A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors August 2, 2017 January 5, 2024
NCT03203876 Completed Phase 1 A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors July 14, 2017 August 6, 2020
NCT03222076 Completed Phase 2 Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer September 28, 2017 September 14, 2022
NCT03241173 Completed Phase 1/Phase 2 A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies October 9, 2017 September 17, 2019
NCT03256136 Completed Phase 2 Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC November 22, 2017 August 19, 2019
NCT03271047 Completed Phase 2 Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation October 18, 2017 February 25, 2021
NCT03287674 Completed Phase 1/Phase 2 TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer October 9, 2017 June 1, 2020
NCT03302234 Completed Phase 3 Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) December 14, 2017 September 7, 2022
NCT03305445 Completed Phase 1 Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL May 14, 2018 April 1, 2021
NCT03335540 Completed Phase 1 An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment May 7, 2018 August 25, 2021
NCT03367715 Completed Phase 2 Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma February 7, 2018 March 17, 2022
NCT00025181 Completed Phase 1 Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery October 2001 June 2005
NCT00032045 Completed Phase 2 Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma January 2002 August 2006
NCT00047164 Completed Phase 1 Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy September 2002 November 2010
NCT00057889 Completed Phase 2 Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer February 2003 February 2008
NCT00058279 Completed Phase 1/Phase 2 Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma February 2003 August 2006
NCT00060372 Completed Phase 1 Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer April 2003
NCT00064129 Completed Phase 1 Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer May 13, 2003 October 1, 2012
NCT00077532 Completed Phase 2 Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma March 2004 February 2008
NCT00084656 Completed Phase 2 Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma May 31, 2004 October 31, 2009
NCT00112580 Completed Phase 2 MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery July 31, 2005 June 30, 2009
NCT00162123 Completed Phase 2 A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies May 2006 April 2014
NCT00170157 Completed Phase 2 Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer June 2004 June 2013
NCT00261365 Completed Phase 1/Phase 2 Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) November 2005 October 2007
NCT00289640 Completed Phase 2 Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma April 2006 July 2007
NCT00324155 Completed Phase 3 Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma August 2006 October 2013
NCT00362713 Completed Phase 1 Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection March 2007 October 2009
NCT00527735 Completed Phase 2 Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) February 2008 December 2011
NCT00623766 Completed Phase 2 Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases July 2008 October 2012
NCT00636168 Completed Phase 3 Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma June 30, 2008 November 26, 2018
NCT00796991 Completed Phase 1 Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine February 2009 October 2012
NCT00836407 Completed Phase 1 Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer February 2009 July 2012
NCT00861614 Completed Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer May 2009 August 2015
NCT00871481 Completed Phase 1/Phase 2 Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma February 2009 October 2013
NCT00920907 Completed Phase 1 Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma August 2009 October 2012
NCT00972933 Completed Early Phase 1 Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma December 2009 September 26, 2017
NCT01024231 Completed Phase 1 Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma December 14, 2009 April 1, 2019
NCT01057810 Completed Phase 3 Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer July 2010 July 2015
NCT01119508 Completed Phase 2 Ipilimumab + Temozolomide in Metastatic Melanoma May 2010 August 2016
NCT01176474 Completed Phase 1 Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma August 13, 2010 January 6, 2023
NCT01194271 Completed Phase 2 Neoadjuvant Ipilimumab in Prostate Cancer September 2010 October 2015
NCT01216696 Completed Phase 2 Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 November 2010 August 2016
NCT01245556 Completed Phase 1 Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma January 2011 November 2012
NCT01285609 Completed Phase 3 Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin January 16, 2011 August 22, 2017
NCT01331525 Completed Phase 2 The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer June 2011 June 2015
NCT01355120 Completed Phase 2 THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease October 2011 September 2013
NCT01363206 Completed Phase 2 Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma May 2011 May 2015
NCT01445379 Completed Phase 1 Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer October 1, 2007 November 13, 2015
NCT01449279 Completed Phase 2 Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy October 2011 December 1, 2016
NCT01450761 Completed Phase 3 Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone December 13, 2011 May 17, 2017
NCT01454102 Completed Phase 1 Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) December 16, 2011 July 23, 2021
NCT01472081 Completed Phase 1 Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) February 9, 2012 June 3, 2021
NCT01473940 Completed Phase 1 Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery June 11, 2012 May 6, 2018
NCT01480323 Completed Phase 2 A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 February 2012 June 2015
NCT01489059 Completed Phase 1 Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma December 2011 June 2014
NCT01497808 Completed Phase 1/Phase 2 RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA November 29, 2011 October 12, 2015
NCT01498978 Completed Phase 2 Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer February 6, 2012 January 19, 2019
NCT01502592 Completed Phase 1 Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer December 2011 December 2014
NCT01515189 Completed Phase 3 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab February 17, 2012 August 17, 2017
NCT01524991 Completed Phase 2 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma January 2012 December 31, 2018
NCT01585194 Completed Phase 2 Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma November 29, 2012 May 14, 2024
NCT01585987 Completed Phase 2 An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy July 2012 April 2015
NCT01611558 Completed Phase 2 Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer August 21, 2012 July 3, 2019
NCT01621490 Completed Phase 1 PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma September 27, 2012 October 25, 2018
NCT01643278 Completed Phase 1 Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic July 2012 June 2016
NCT01673854 Completed Phase 2 Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma September 13, 2012 May 12, 2015
NCT01681212 Completed Phase 2 Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma October 2012 May 2014
NCT01693783 Completed Phase 2 Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer December 3, 2012 November 24, 2021
NCT01703507 Completed Phase 1 Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma November 9, 2012 April 11, 2018
NCT01711515 Completed Phase 1 Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer October 1, 2012 July 17, 2020
NCT01714739 Completed Phase 1/Phase 2 A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors October 7, 2012 December 13, 2019
NCT01729806 Completed Phase 1 Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma November 19, 2012 March 30, 2018
NCT01738139 Completed Phase 1 Ipilimumab and Imatinib Mesylate in Advanced Cancer February 19, 2013 December 13, 2023
NCT01740297 Completed Phase 1/Phase 2 Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma February 7, 2013 March 9, 2021
NCT01750580 Completed Phase 1 Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor December 2012 April 2015
NCT01750983 Completed Phase 1 Ipilimumab and Lenalidomide in Advanced Cancer March 2013 February 21, 2019
NCT01757639 Completed Phase 1 Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia December 14, 2012
NCT01767454 Completed Phase 1 Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma February 12, 2013 September 4, 2015
NCT01783938 Completed Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) April 30, 2013 August 12, 2020
NCT01804465 Completed Phase 2 Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer April 22, 2014 August 31, 2020
NCT01820754 Completed Phase 2 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) March 2013 April 30, 2018
NCT01822509 Completed Phase 1 Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant May 16, 2013 June 10, 2021
NCT01827111 Completed Phase 2 Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma April 25, 2013 September 21, 2020
NCT01832870 Completed Phase 1 Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer April 2013 February 2016
NCT01866319 Completed Phase 3 Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) August 28, 2013 June 3, 2019
NCT01896869 Completed Phase 2 FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer November 2013 May 3, 2019
NCT01919619 Completed Phase 2 Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies November 4, 2013 May 3, 2024
NCT01927419 Completed Phase 2 Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma August 23, 2013 February 26, 2021
NCT01935921 Completed Phase 1 Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer April 9, 2013 July 6, 2018
NCT01990859 Completed Phase 2 Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients December 2013 February 2015
NCT01998126 Completed Phase 1 Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer December 2, 2013 March 29, 2018
NCT02009397 Completed Phase 1/Phase 2 A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients February 2012 November 2016
NCT02027935 Completed Phase 2 CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma January 22, 2015 April 12, 2024
NCT02032810 Completed Phase 1 Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma January 7, 2014 September 25, 2019
NCT02039674 Completed Phase 1/Phase 2 A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) February 21, 2014 October 18, 2021
NCT02050594 Completed Ipilimumab 12-month Intensive Pharmacovigilance Protocol February 2014 February 2015
NCT02073123 Completed Phase 1/Phase 2 Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma July 2014 July 3, 2019
NCT02089685 Completed Phase 1/Phase 2 Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) March 17, 2014 April 1, 2021
NCT02094391 Completed Phase 2 Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma March 2014 February 2016
NCT02107755 Completed Phase 2 Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma September 5, 2014 August 16, 2021
NCT02113657 Completed Early Phase 1 T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer August 20, 2014 November 4, 2019
NCT02115139 Completed Phase 2 GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases April 4, 2014 July 31, 2018
NCT02115243 Completed Phase 1 Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma May 2014 December 7, 2015
NCT02117362 Completed Phase 1 Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma May 8, 2014 November 28, 2018
NCT02154490 Completed Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer July 8, 2014 April 15, 2022
NCT02158520 Completed Phase 2 Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery October 18, 2013 October 30, 2019
NCT02174172 Completed Phase 1 A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors August 18, 2014 November 25, 2019
NCT02221739 Completed Phase 1/Phase 2 Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) July 1, 2014 October 27, 2015
NCT02224768 Completed YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey July 2015 November 2015
NCT02239900 Completed Phase 1 Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors August 26, 2014 October 25, 2019
NCT02254772 Completed Phase 1/Phase 2 A Phase I/II Study of Intratumoral Injection of SD-101 September 2014 January 26, 2017
NCT02279732 Completed Phase 3 Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin October 13, 2014 May 3, 2018
NCT02279862 Completed Phase 2 Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive December 2, 2014 December 15, 2016
NCT02304458 Completed Phase 1/Phase 2 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas March 30, 2015 March 31, 2023
NCT02307149 Completed Phase 1 Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) May 5, 2015 November 5, 2019
NCT02311920 Completed Phase 1 Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma April 16, 2015 December 22, 2022
NCT02320058 Completed Phase 2 An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself March 5, 2015 September 8, 2020
NCT02397720 Completed Phase 2 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia April 7, 2015 October 9, 2023
NCT02403778 Completed Phase 2 Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma December 17, 2015 January 18, 2023
NCT02406183 Completed Phase 1 Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma March 2015 August 2016
NCT02423928 Completed Phase 1 Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer May 2015 August 16, 2019
NCT02467361 Completed Phase 1 A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers August 2015 January 29, 2021
NCT02488759 Completed Phase 1/Phase 2 An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors October 13, 2015 October 24, 2022
NCT02500797 Completed Phase 2 Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery August 13, 2015 April 1, 2023
NCT02516527 Completed Phase 1 A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors October 16, 2015 September 20, 2018
NCT02519322 Completed Phase 2 Neoadjuvant and Adjuvant Checkpoint Blockade February 2, 2016 January 26, 2023
NCT02538666 Completed Phase 3 An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy October 13, 2015 November 11, 2021
NCT02545075 Completed Phase 3 A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine October 31, 2015 April 19, 2019
NCT02599402 Completed Phase 3 Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma December 20, 2015 February 10, 2020
NCT02601014 Completed Phase 2 Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 March 15, 2016 October 6, 2021
NCT02626962 Completed Phase 2 Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma April 2016 July 22, 2021
NCT02631447 Completed Phase 2 Sequential Combo Immuno and Target Therapy (SECOMBIT) Study November 14, 2016 May 31, 2024
NCT02644967 Completed Phase 2 A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma December 2015 May 2021
NCT02658890 Completed Phase 1/Phase 2 An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread April 14, 2016 October 26, 2021
NCT02659059 Completed Phase 2 Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer February 15, 2016 March 7, 2022
NCT02659540 Completed Phase 1 Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma October 13, 2016 July 27, 2020
NCT02662725 Completed Phase 2 Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases September 2012 December 2015
NCT02731729 Completed Phase 2 Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy June 21, 2016 February 13, 2019
NCT02737475 Completed Phase 1/Phase 2 An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread June 17, 2016 November 2, 2020
NCT02739386 Completed Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases February 29, 2016 March 30, 2017
NCT02741570 Completed Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck October 5, 2016 September 22, 2022
NCT02823574 Completed Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck November 8, 2016 April 21, 2022
NCT02829931 Completed Phase 1 Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas August 22, 2016 November 22, 2022
NCT02833233 Completed N/A A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer June 2016 June 7, 2024
NCT02864251 Completed Phase 3 A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy March 17, 2017 October 17, 2022
NCT02866383 Completed Phase 2 Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients November 2016 November 30, 2022
NCT02880020 Completed Phase 2 Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery December 14, 2016 August 9, 2022
NCT02899299 Completed Phase 3 Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients November 29, 2016 April 28, 2023
NCT02904226 Completed Phase 1/Phase 2 JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors August 2016 July 1, 2020
NCT02905266 Completed Phase 3 A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma October 27, 2016 October 25, 2019
NCT02913313 Completed Phase 1/Phase 2 A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors November 30, 2016 January 25, 2024
NCT02935634 Completed Phase 2 A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer November 29, 2016 May 11, 2022
NCT02935790 Completed Phase 1 Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab September 30, 2016 April 7, 2017
NCT02939300 Completed Phase 2 Ipilimumab and Nivolumab in Leptomeningeal Metastases February 15, 2018 July 22, 2021
NCT02941744 Completed Phase 1/Phase 2 A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases March 2016 January 2019
NCT02960906 Completed Phase 2 A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer May 31, 2017 February 15, 2021
NCT02970981 Completed Phase 2 Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma November 29, 2016 May 2, 2022
NCT02977156 Completed Phase 1 Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. January 3, 2017 June 6, 2022
NCT02982954 Completed Phase 4 A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer January 16, 2017 October 6, 2021
NCT02996110 Completed Phase 2 A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma February 2, 2017 November 23, 2021
NCT03001882 Completed Phase 2 An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) March 29, 2017 April 24, 2023
NCT03003637 Completed Phase 1/Phase 2 ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma February 28, 2017 February 12, 2021
NCT03013491 Completed Phase 1/Phase 2 PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas January 2017 October 6, 2021
NCT03373188 Completed Phase 1 VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer December 15, 2017 October 28, 2021
NCT03387761 Completed Phase 1 Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy January 15, 2018 September 13, 2021
NCT03396952 Completed Phase 2 Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma April 19, 2018 June 30, 2022
NCT03408587 Completed Phase 1 CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) January 29, 2018 May 22, 2019
NCT03409198 Completed Phase 2 Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer January 21, 2018 May 11, 2022
NCT03409848 Completed Phase 2 Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma March 1, 2018 March 5, 2022
NCT03416244 Completed Phase 2 A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer February 21, 2018 November 19, 2021
NCT03425292 Completed Phase 1 A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer March 1, 2018 October 27, 2023
NCT03453892 Completed Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition April 1, 2017 December 30, 2022
NCT03468985 Completed Phase 2 Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer May 7, 2018 December 21, 2022
NCT03525795 Completed Phase 1 ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors December 14, 2017 June 12, 2019
NCT03532217 Completed Phase 1 Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer September 14, 2018 July 25, 2022
NCT03573947 Completed Phase 2 Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC October 2, 2018 June 15, 2023
NCT03639714 Completed Phase 1/Phase 2 A Study of a Personalized Neoantigen Cancer Vaccine February 13, 2019 November 10, 2022
NCT03668119 Completed Phase 2 A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) October 31, 2018 August 2, 2023
NCT03711188 Completed Phase 2 A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma October 4, 2018 December 2, 2021
NCT03749460 Completed Phase 1/Phase 2 Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers January 15, 2019 November 5, 2023
NCT03798639 Completed Phase 1 Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer January 7, 2019 December 2, 2022
NCT03832621 Completed Phase 2 NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer March 25, 2019 September 30, 2021
NCT03922880 Completed Phase 1 Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma April 16, 2019 January 20, 2023
NCT03953235 Completed Phase 1/Phase 2 A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens July 18, 2019 March 10, 2023
NCT03956680 Completed Phase 1 An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers March 26, 2019 April 17, 2024
NCT03978611 Completed Phase 1 A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment December 9, 2021 July 26, 2023
NCT03989362 Completed Phase 2 Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer June 6, 2019 March 15, 2022
NCT04084951 Completed Phase 1 Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors January 28, 2020 February 9, 2023
NCT04118166 Completed Phase 2 Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma October 1, 2019 April 26, 2022
NCT04124601 Completed Phase 2 Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer June 1, 2020 March 15, 2024
NCT04132817 Completed Phase 1 A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread September 22, 2020 August 15, 2022
NCT04382664 Completed Phase 2 UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma June 15, 2020 April 10, 2024
NCT04513522 Completed Phase 4 A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India December 17, 2020 January 4, 2024
NCT04518046 Completed Phase 1 Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies August 11, 2020 June 30, 2023
NCT05005273 Completed Phase 2 A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer October 3, 2022 December 27, 2022
NCT05041062 Completed Phase 2 A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma December 1, 2021 April 13, 2023
NCT05116202 Completed Phase 1/Phase 2 A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) February 2, 2022 March 27, 2024
NCT00495066 No longer available Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
NCT03460782 No longer available An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
NCT02186249 No longer available Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma
NCT06163820 Not yet recruiting Phase 1/Phase 2 Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases January 30, 2024 January 30, 2026
NCT06240143 Not yet recruiting Phase 1/Phase 2 Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma February 2024 May 2026
NCT02498756 Not yet recruiting Phase 2 Cytokine-induced Killer Study for Patients With Stage II Melanoma August 2015 August 2040
NCT06324240 Not yet recruiting Phase 1 Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer June 1, 2024 December 31, 2026
NCT06364917 Not yet recruiting Phase 2 DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC October 31, 2024 June 2027
NCT06410534 Not yet recruiting Phase 2 A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer June 23, 2024 September 1, 2032
NCT06388369 Not yet recruiting Phase 1/Phase 2 Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer May 2024 September 2028
NCT06365619 Not yet recruiting Phase 2 Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma August 2024 August 2029
NCT06377111 Not yet recruiting Phase 1 A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma May 2024 May 2026
NCT05457959 Not yet recruiting Phase 1 Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant December 1, 2024 May 1, 2030
NCT03799445 Recruiting Phase 2 Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma July 25, 2019 June 30, 2025
NCT03815890 Recruiting Phase 2 Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO October 4, 2019 January 1, 2033
NCT03026140 Recruiting Phase 2 Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer March 29, 2017 December 2024
NCT05215470 Recruiting Phase 2 CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy January 18, 2022 November 30, 2026
NCT04620200 Recruiting Phase 2 Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery August 11, 2020 November 1, 2024
NCT05921760 Recruiting Phase 1/Phase 2 Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma October 23, 2023 March 2026
NCT03406247 Recruiting Phase 2 Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma February 12, 2018 May 2026
NCT04697576 Recruiting Phase 1 Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma October 20, 2021 December 31, 2025
NCT04709276 Recruiting Phase 2 A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer June 7, 2021 June 2027
NCT05779423 Recruiting Phase 2 Cryoablation+Ipilimumab+Nivolumab in Melanoma September 23, 2023 January 1, 2028
NCT06049576 Recruiting Phase 1 Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma October 6, 2023 March 14, 2026
NCT04823403 Recruiting Phase 1 Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma November 13, 2020 November 2024
NCT04840589 Recruiting Phase 1 Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors February 2, 2022 January 1, 2026
NCT05578872 Recruiting Phase 1/Phase 2 A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). December 16, 2022 December 2024
NCT04855929 Recruiting Phase 1 A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer. May 25, 2021 January 2025
NCT03866382 Recruiting Phase 2 Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors May 13, 2019 February 28, 2025
NCT02922764 Recruiting Phase 1 A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer November 2016 May 2024
NCT03391869 Recruiting Phase 3 Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer December 29, 2017 December 31, 2025
NCT03138161 Recruiting Phase 1/Phase 2 SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma April 13, 2017 March 31, 2025
NCT03899155 Recruiting Phase 2 Pan Tumor Rollover Study August 9, 2019 August 25, 2029
NCT04929041 Recruiting Phase 2/Phase 3 Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative October 7, 2022 December 31, 2027
NCT04933903 Recruiting Phase 2 BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab October 5, 2021 January 2025
NCT03520491 Recruiting Phase 2 A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy April 25, 2018 January 2025
NCT05199285 Recruiting Phase 2 A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab January 19, 2023 January 31, 2027
NCT04966676 Recruiting Phase 2 Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer January 24, 2022 November 1, 2025
NCT05188118 Recruiting Early Phase 1 Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma February 24, 2023 December 2025
NCT03604978 Recruiting Phase 1/Phase 2 Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma June 17, 2019 December 31, 2024
NCT04988841 Recruiting Phase 2 Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma January 20, 2022 June 1, 2024
NCT04996823 Recruiting Phase 2 Axitinib + Ipilimumab in Advanced Melanoma August 4, 2021 August 2027
NCT05012254 Recruiting Phase 2 Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases November 18, 2021 December 15, 2026
NCT05176483 Recruiting Phase 1 Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors December 14, 2021 May 2026
NCT06399419 Recruiting Phase 1 CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer June 19, 2024 October 19, 2026
NCT05048212 Recruiting Phase 2 A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases September 20, 2022 July 31, 2024
NCT05088889 Recruiting Phase 1 Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer January 25, 2022 July 1, 2024
NCT05112601 Recruiting Phase 2 Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma June 2, 2022 April 30, 2026
NCT06097728 Recruiting Phase 3 MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma November 9, 2023 March 13, 2028
NCT05136677 Recruiting Phase 2 A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants January 25, 2022 October 8, 2026
NCT05926960 Recruiting Phase 2 A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma June 13, 2023 May 23, 2027
NCT05144529 Recruiting Phase 2 A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC March 22, 2022 December 2025
NCT03645928 Recruiting Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors May 7, 2019 August 9, 2029
NCT06250335 Recruiting Phase 2 Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients March 1, 2024 January 23, 2029
NCT03388632 Recruiting Phase 1 Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers February 5, 2018 December 1, 2024
NCT06295159 Recruiting Early Phase 1 Biomarker Driven Patient Selection Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma February 28, 2024 March 2027
NCT03646617 Recruiting Phase 2 Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma November 27, 2018 December 31, 2025
NCT03521830 Recruiting Phase 2 Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma November 27, 2018 March 2027
NCT04003649 Recruiting Phase 1 IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM December 2, 2019 July 31, 2025
NCT03166397 Recruiting Phase 2 Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients June 5, 2017 June 1, 2026
NCT05715229 Recruiting Phase 2 Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy September 29, 2023 April 28, 2026
NCT04462406 Recruiting Phase 2 Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial February 9, 2021 August 29, 2026
NCT04464759 Recruiting Phase 1/Phase 2 A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma October 21, 2020 October 30, 2025
NCT04465643 Recruiting Phase 1 Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor June 8, 2021 August 2026
NCT04472767 Recruiting Phase 2 Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma August 7, 2020 September 1, 2027
NCT05647265 Recruiting Phase 2 Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma March 14, 2023 December 15, 2024
NCT05289193 Recruiting Phase 2 CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma March 11, 2022 March 11, 2025
NCT04495257 Recruiting Phase 1 A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) September 14, 2020 February 2025
NCT05219435 Recruiting Phase 2 Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial Cancer July 6, 2022 December 2025
NCT04511013 Recruiting Phase 2 A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases January 6, 2021 June 30, 2027
NCT04562129 Recruiting Phase 2 IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients September 24, 2020 September 2029
NCT06047379 Recruiting Phase 1/Phase 2 Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis November 1, 2023 August 31, 2026
NCT03546686 Recruiting Phase 2 Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer November 12, 2019 June 2026
NCT03739710 Recruiting Phase 2 Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) January 24, 2019 July 8, 2025
NCT06031233 Recruiting Phase 4 Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie September 1, 2023 December 2024
NCT05721846 Recruiting Phase 1 Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer May 3, 2023 December 2025
NCT03097939 Recruiting Phase 2 Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma March 31, 2017 December 31, 2024
NCT04388852 Recruiting Phase 1 DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers August 20, 2020 December 31, 2026
NCT05327686 Recruiting Phase 2 Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study June 30, 2022 June 15, 2032
NCT04413123 Recruiting Phase 2 Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC November 5, 2020 December 20, 2025
NCT04416568 Recruiting Phase 2 Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers August 14, 2020 October 2025
NCT05310643 Recruiting Phase 2 Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer Resistant to Anti-PD1 Monotherapy May 5, 2022 September 30, 2027
NCT04008030 Recruiting Phase 3 A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) August 5, 2019 June 10, 2026
NCT03340129 Recruiting Phase 2 Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) August 14, 2019 August 2025
NCT04013854 Recruiting Phase 2 Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab January 1, 2020 August 2026
NCT03104439 Recruiting Phase 2 Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer May 10, 2017 October 2026
NCT05501054 Recruiting Phase 1/Phase 2 Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma. February 9, 2023 November 1, 2026
NCT02408861 Recruiting Phase 1 Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery October 21, 2015 July 1, 2024
NCT05896839 Recruiting Phase 1/Phase 2 Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer August 11, 2024 January 31, 2027
NCT02339571 Recruiting Phase 2/Phase 3 A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma November 23, 2015 June 30, 2033
NCT04080804 Recruiting Phase 2 Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer January 8, 2020 September 30, 2027
NCT05928806 Recruiting Phase 2 Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial September 25, 2023 October 12, 2026
NCT04107168 Recruiting Microbiome Immunotherapy Toxicity and Response Evaluation July 8, 2020 July 8, 2025
NCT04117087 Recruiting Phase 1 Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer May 28, 2020 August 8, 2025
NCT06342037 Recruiting Phase 2 NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial June 12, 2024 April 1, 2030
NCT06362369 Recruiting Phase 1/Phase 2 A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy May 20, 2024 December 31, 2028
NCT06364631 Recruiting Phase 3 CARE1 Pragmatic Clinical Trial April 12, 2024 May 5, 2032
NCT05444530 Recruiting Phase 1 A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms July 21, 2022 November 27, 2027
NCT03682276 Recruiting Phase 1/Phase 2 Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma March 1, 2019 December 1, 2023
NCT05407441 Recruiting Phase 1/Phase 2 Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors August 10, 2023 February 1, 2029
NCT05401786 Recruiting Phase 2 Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC January 3, 2023 December 2025
NCT03690986 Recruiting Phase 1 VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer November 1, 2018 July 26, 2025
NCT03233139 Recruiting Phase 1 Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies June 21, 2017 March 27, 2030
NCT04248569 Recruiting Phase 1 DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma April 20, 2020 March 1, 2027
NCT05987332 Recruiting Phase 2/Phase 3 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma October 31, 2023 January 15, 2028
NCT05361720 Recruiting Phase 2 Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study December 1, 2022 July 1, 2026
NCT04290546 Recruiting Phase 1 CIML NK Cell in Head & Neck Cancer July 20, 2020 December 1, 2024
NCT05732389 Recruiting Phase 2 Immunotherapy in Patients With Early dMMR Rectal Cancer February 1, 2023 February 2027
NCT05904080 Recruiting Phase 2 Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer February 19, 2024 June 16, 2028
NCT05341349 Recruiting Phase 1 Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases October 13, 2022 March 6, 2025
NCT05501665 Suspended Phase 1/Phase 2 Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer May 9, 2023 February 1, 2027
NCT05836571 Suspended Phase 2 Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma October 25, 2023 May 15, 2026
NCT04145115 Suspended Phase 2 A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden December 24, 2020 May 31, 2025
NCT03604991 Suspended Phase 2/Phase 3 Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery May 3, 2019 January 31, 2026
NCT04751370 Suspended Phase 2 Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer February 8, 2022 December 31, 2026
NCT03958383 Suspended Phase 1/Phase 2 IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma January 30, 2020 August 15, 2025
NCT04091750 Suspended Phase 2 Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma March 2, 2020 May 2024
NCT03425331 Suspended Phase 2 Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC February 28, 2018 August 28, 2025
NCT01896999 Suspended Phase 1/Phase 2 Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma March 7, 2014 March 20, 2025
NCT05498792 Suspended Early Phase 1 Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma November 30, 2022 September 2, 2025
NCT01409174 Terminated Phase 1 IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma February 2013 May 2016
NCT03509584 Terminated Phase 1 Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients June 7, 2018 July 2, 2019
NCT03168464 Terminated Phase 1/Phase 2 Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) October 9, 2017 March 11, 2022
NCT03597282 Terminated Phase 1 A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma October 8, 2018 August 11, 2020
NCT03110107 Terminated Phase 1/Phase 2 First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors May 4, 2017 April 4, 2024
NCT03663166 Terminated Phase 1/Phase 2 Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) November 20, 2018 October 22, 2021
NCT03693846 Terminated Phase 2 Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors February 15, 2019 March 6, 2021
NCT03707457 Terminated Phase 1 Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma March 22, 2019 June 18, 2020
NCT03724968 Terminated Phase 2 Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression January 17, 2019 May 28, 2020
NCT03728465 Terminated Phase 2 Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma April 10, 2018 January 1, 2021
NCT03091491 Terminated Phase 2 Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer April 7, 2017 November 18, 2019
NCT03026166 Terminated Phase 1/Phase 2 A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer March 30, 2017 July 3, 2019
NCT03009058 Terminated Phase 1/Phase 2 Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer May 24, 2017 August 30, 2017
NCT02978443 Terminated Phase 2 A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab July 26, 2017 August 2, 2022
NCT03878524 Terminated Phase 1 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial April 1, 2020 December 10, 2020
NCT03903640 Terminated Phase 2 Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis October 14, 2019 November 3, 2021
NCT02892734 Terminated Phase 2 Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer September 18, 2017 February 4, 2019
NCT02846376 Terminated Phase 1 Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant March 8, 2019 December 21, 2023
NCT02750514 Terminated Phase 2 An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer May 9, 2016 January 29, 2020
NCT02723006 Terminated Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma June 22, 2016 May 11, 2018
NCT02681302 Terminated Phase 1/Phase 2 Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence June 7, 2016 May 10, 2024
NCT03993379 Terminated Phase 2 PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors November 20, 2019 May 21, 2020
NCT02675439 Terminated Phase 1 Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas April 28, 2016 August 6, 2020
NCT02506114 Terminated Phase 2 Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer October 6, 2016 April 22, 2020
NCT02385669 Terminated Phase 1/Phase 2 A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma April 2015 September 18, 2019
NCT04088500 Terminated Phase 2 A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma September 3, 2020 November 15, 2021
NCT02203604 Terminated Phase 2 High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery November 26, 2014 January 27, 2020
NCT04185311 Terminated Phase 1 Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted July 10, 2019 May 17, 2023
NCT02097732 Terminated Phase 2 Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery April 2014 July 2020
NCT02054520 Terminated Phase 2 Immunotherapy Study for Patients With Stage IV Melanoma June 2014 January 5, 2021
NCT04258150 Terminated Phase 2 Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer April 16, 2020 November 23, 2021
NCT02009384 Terminated Phase 2 Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox January 2012 October 2014
NCT04311710 Terminated Phase 1 A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types June 25, 2020 January 18, 2023
NCT01970527 Terminated Phase 2 Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma March 2014 June 21, 2019
NCT04319224 Terminated Phase 1/Phase 2 Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors March 10, 2020 January 3, 2023
NCT04340193 Terminated Phase 3 A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer September 15, 2020 December 12, 2023
NCT01950195 Terminated Phase 1 SRS (Stereotactic Radiosurgery) Plus Ipilimumab September 2013
NCT01940809 Terminated Phase 1 Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery August 28, 2013 March 4, 2022
NCT04429321 Terminated Phase 1 Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary August 26, 2020 January 31, 2024
NCT04434560 Terminated Phase 2 Neoadjuvant Immunotherapy in Brain Metastases November 4, 2020 June 17, 2021
NCT01856023 Terminated Phase 4 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma May 2013 July 2015
NCT01838200 Terminated Phase 1 Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma March 2014 August 17, 2015
NCT01810016 Terminated Phase 1 NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma January 24, 2014 May 17, 2016
NCT01769222 Terminated Phase 1 Ipilimumab and Local Radiation for Selected Solid Tumors February 2013 June 2015
NCT01730157 Terminated Early Phase 1 Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases December 2012 February 2016
NCT04610658 Terminated Phase 1 Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC November 23, 2020 March 24, 2023
NCT04635735 Terminated Phase 1/Phase 2 Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma January 12, 2020 February 2, 2023
NCT04655157 Terminated Phase 1/Phase 2 Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma May 28, 2021 September 20, 2022
NCT01709162 Terminated Phase 2 Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma March 2013 July 2014
NCT01696045 Terminated Phase 2 Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma November 12, 2012 July 31, 2016
NCT04840615 Terminated Phase 1 Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma June 11, 2021 January 12, 2022
NCT01689974 Terminated Phase 2 Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma January 2013 March 2015
NCT01604889 Terminated Phase 1/Phase 2 A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma March 2012 December 27, 2016
NCT04892043 Terminated Phase 1 Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors August 19, 2021 November 2, 2023
NCT04894994 Terminated Phase 2 FLX475 in Combination With Ipilimumab in Advanced Melanoma September 3, 2021 September 13, 2022
NCT04899921 Terminated Phase 2 Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets June 30, 2021 May 29, 2023
NCT01590082 Terminated Phase 1/Phase 2 Doxycycline, Temozolomide and Ipilimumab in Melanoma November 2012 July 2015
NCT01557114 Terminated Phase 1 Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma March 2011 March 2016
NCT01471197 Terminated Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer July 2012 February 2013
NCT05074992 Terminated Phase 2 A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma August 24, 2022 May 2, 2023
NCT05116917 Terminated Phase 2 Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. November 5, 2021 October 19, 2023
NCT03203304 Terminated Phase 1 Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer August 25, 2017 March 13, 2019
NCT01377389 Terminated Phase 2 Ipilimumab + Androgen Depravation Therapy in Prostate Cancer June 17, 2011 April 7, 2017
NCT00140855 Terminated Phase 2 A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma June 8, 2005 July 1, 2007
NCT00089076 Terminated Phase 1/Phase 2 MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma June 2004 October 2009
NCT05456165 Terminated Phase 2 Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer May 19, 2022 September 1, 2022
NCT03347123 Terminated Phase 1/Phase 2 A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) March 21, 2018 January 29, 2021
NCT03342417 Terminated Phase 2 Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients February 14, 2018 May 29, 2019
NCT03406715 Terminated Phase 2 Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC) March 15, 2018 May 16, 2022
NCT00039091 Terminated Phase 1 Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer March 2002 November 21, 2007
NCT03420521 Terminated Phase 2 Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors March 9, 2018 November 24, 2021
NCT03422094 Terminated Phase 1 Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma October 31, 2018 December 31, 2020
NCT03425461 Terminated Phase 1 Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma June 14, 2018 March 4, 2021
NCT03437200 Terminated Phase 2 Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer January 17, 2019 October 7, 2022
NCT03444753 Terminated Phase 1 An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed April 5, 2018 February 14, 2022
NCT03445533 Terminated Phase 3 A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma May 30, 2018 June 1, 2021
NCT03251924 Terminated Phase 1/Phase 2 A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors September 1, 2017 December 20, 2021
NCT03461952 Terminated Phase 2 Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) March 11, 2019 February 9, 2022
NCT02948348 Unknown status Phase 1/Phase 2 Study to Nivolumab Following Preoperative Chemoradiotherapy October 2016 August 2022
NCT03296137 Unknown status Phase 1/Phase 2 Adoptive Cell Therapy Across Cancer Diagnoses October 13, 2017 September 30, 2020
NCT02982486 Unknown status Phase 2 A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma December 2017 December 2020
NCT03527251 Unknown status Phase 1 Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC May 15, 2018 December 31, 2019
NCT01565837 Unknown status Phase 2 Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma August 2012 November 2017
NCT02608437 Unknown status Phase 1 A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients October 2015 October 2018
NCT04611126 Unknown status Phase 1/Phase 2 T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer April 22, 2021 December 2023
NCT04134182 Unknown status Phase 2 Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. October 16, 2019 December 2021
NCT03784040 Unknown status Phase 1 Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study. February 21, 2019 March 1, 2024
NCT03177239 Unknown status Phase 2 Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) October 19, 2017 December 31, 2022
NCT03219671 Unknown status Phase 2 Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) April 1, 2018 September 1, 2022
NCT03161756 Unknown status Phase 1/Phase 2 Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma December 7, 2017 December 2023
NCT03098160 Unknown status Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab May 10, 2017 April 2019
NCT02913417 Unknown status Phase 1/Phase 2 Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases October 10, 2016 June 2023
NCT02046733 Unknown status Phase 2 Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease July 28, 2014 June 2022
NCT00732186 Withdrawn Phase 1 Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia August 2009 February 2011
NCT01409187 Withdrawn Phase 1/Phase 2 IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma October 2011
NCT01530984 Withdrawn Phase 2 Ipilimumab and GMCSF Immunotherapy for Prostate Cancer June 2015 December 2018
NCT01689870 Withdrawn Phase 1/Phase 2 Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma March 2014 August 2014
NCT04500548 Withdrawn Phase 1 Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study January 28, 2021 June 21, 2022
NCT00357461 Withdrawn Phase 2 Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma May 2006
NCT04495010 Withdrawn Phase 2 Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants March 31, 2021 October 23, 2027
NCT03477864 Withdrawn Phase 1 Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer December 24, 2018 November 4, 2019
NCT04430985 Withdrawn Phase 2 FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer September 30, 2020 September 6, 2021
NCT01913691 Withdrawn Phase 2 Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma July 9, 2013 February 3, 2014
NCT04315155 Withdrawn Phase 1 Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation October 2020 September 2025
NCT03126461 Withdrawn Phase 2 SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients March 1, 2018 December 31, 2022
NCT04149275 Withdrawn Phase 2 Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma February 2021 February 2021
NCT02210104 Withdrawn Phase 1 Adoptive Therapy Using Antigen-Specific CD4 T-Cells December 2016
NCT04060407 Withdrawn Phase 1/Phase 2 CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) June 15, 2021 December 30, 2023
NCT02452281 Withdrawn Phase 1/Phase 2 Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma December 2015 December 2018
NCT03220009 Withdrawn Phase 2 Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma November 3, 2017 July 1, 2021
NCT04007588 Withdrawn Phase 2 A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma September 6, 2019 December 19, 2019
NCT03982121 Withdrawn Phase 1 Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy June 4, 2019 February 12, 2020
NCT03326258 Withdrawn Phase 1/Phase 2 Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery April 20, 2018 April 20, 2018
NCT03283046 Withdrawn Phase 1 Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma October 2017 October 2020
NCT03048136 Withdrawn Phase 3 A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer March 9, 2018 September 29, 2019
NCT03149159 Withdrawn Phase 2 Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab April 1, 2018 April 1, 2018
NCT03767439 Withdrawn Phase 2 Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome July 2019 February 2020
NCT04151563 Withdrawn Phase 1/Phase 2 A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy April 15, 2021 May 13, 2026
NCT00803374 Withdrawn Phase 1 Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma November 2010 January 2013